MARLBOROUGH, Mass., Oct. 27, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $2.932 billion during the third quarter of 2021, growing 10.3 percent on a reported basis, 9.7 percent on an operational1 basis and 10.6 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income available to common stockholders of $405 million or $0.28 per share (EPS), compared to a GAAP net loss available to common shareholders of $169 million or $(0.12) per share a year ago, and achieved adjusted EPS of $0.41 for the period, compared to $0.37 a year ago.
Read more at prnewswire.comProvided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.